CVAC Jan 2023 60.000 call
| Previous close | 0.5000 |
| Open | 0.5000 |
| Bid | 0.0000 |
| Ask | 0.4000 |
| Strike | 60.00 |
| Expiry date | 2023-01-20 |
| Day's range | 0.5000 - 0.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 189 |
- EQS Group
CureVac Announces Voting Results of General Meeting
Issuer: CureVac / Key word(s): AGM/EGM22.06.2022 / 22:05 The issuer is solely responsible for the content of this announcement. CureVac Announces Voting Results of General Meeting TÜBINGEN, Germany / BOSTON, USA – June 22, 2022 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general meeting. The shareholders o
- Simply Wall St.
What Type Of Shareholders Own The Most Number of CureVac N.V. (NASDAQ:CVAC) Shares?
The big shareholder groups in CureVac N.V. ( NASDAQ:CVAC ) have power over the company. Insiders often own a large...
- EQS Group
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
Issuer: CureVac / Key word(s): Takeover08.06.2022 / 22:10 The issuer is solely responsible for the content of this announcement.CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform Acquisition extends CureVac’s capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients’ immune systems to fight cancer Frame’s platform offers potential to develop off-the-shelf and pers
